145.70

3.84% 5.39

After Hours: 145.70

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $145.70, with a volume of 152.93K. It is up +3.84% in the last 24 hours and up +34.08% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Previous Close:

$140.31

Open:

$141.49

24h Volume:

152.93K

Relative Volume:

0.58

Market Cap:

$2.09B

Revenue:

$1.30M

Net Income/Loss:

$-49.30M

P/E Ratio:

-34.95

EPS:

-4.1688

Net Cash Flow:

$-25.01M

1W Performance:

-4.66%

1M Performance:

+34.08%

6M Performance:

+44.21%

1Y Performance:

+485.14%

1-Day Range:

$138.29

$147.96

1-Week Range:

$135.00

$150.40

52-Week Range:

$24.07

$161.38

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	145.70	2.01B	1.30M	-49.30M	-25.01M	-4.1688
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

Jul 04, 2026

PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz

Jul 04, 2026

Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView

Jul 04, 2026

Jul 01, 2026

Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo

Jul 01, 2026

Jun 30, 2026

Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz

Jun 30, 2026

Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart

Jun 30, 2026

Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa

Jun 30, 2026

Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com

Jun 30, 2026

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail

Jun 30, 2026

Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire

Jun 30, 2026

Jun 29, 2026

Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com

Jun 29, 2026

Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026

Palvella submits FDA NDA for QTORIN gel - grafa.com

Jun 29, 2026

Palvella submits first module of NDA for rare skin disease therapy - Investing.com

Jun 29, 2026

Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative

Jun 29, 2026

Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - Yahoo Finance

Jun 27, 2026

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - The Motley Fool

Jun 27, 2026

Jun 26, 2026

Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView

Jun 26, 2026

Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA) - TradingView

Jun 26, 2026